{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:21:29Z","timestamp":1792027289832,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s10147-025-02859-2","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T08:52:57Z","timestamp":1756803177000},"page":"2266-2276","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neutrophil-to-lymphocyte ratio affects the impact of proton pump inhibitors on efficacy of immune checkpoint inhibitors in patients with non\u2011small-cell lung cancer"],"prefix":"10.1007","volume":"30","author":[{"given":"Tomoki","family":"Hori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7513-6725","authenticated-orcid":false,"given":"Kazuhiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takefumi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Ikushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Omura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuko","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"2859_CR1","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","volume":"94","author":"N Duma","year":"2019","unstructured":"Duma N, Santana-Davila R, Molina JR (2019) Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatmeNT. Mayo Clin Proc 94:1623\u20131640. https:\/\/doi.org\/10.1016\/j.mayocp.2019.01.013","journal-title":"Mayo Clin Proc"},{"key":"2859_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1634\/theoncologist.2016-0189","volume":"22","author":"B Herzberg","year":"2017","unstructured":"Herzberg B, Campo MJ, Gainor JF (2017) Immune checkpoint inhibitors in non-small cell lung cancer. Oncologist 22:81\u201388. https:\/\/doi.org\/10.1634\/theoncologist.2016-0189","journal-title":"Oncologist"},{"key":"2859_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/10600280211033938","volume":"56","author":"K Peng","year":"2022","unstructured":"Peng K, Chen K, Teply BA et al (2022) Impact of proton pump inhibitor use on the effectiveness of immune checkpoint inhibitors in advanced cancer patients. Ann Pharmacother 56:377\u2013386. https:\/\/doi.org\/10.1177\/10600280211033938","journal-title":"Ann Pharmacother"},{"key":"2859_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106972","volume":"88","author":"M Li","year":"2020","unstructured":"Li M, Zeng C, Yao J et al (2020) The association between proton pump inhibitors use and clinical outcome of patients receiving immune checkpoint inhibitors therapy. Int Immunopharmacol 88:106972. https:\/\/doi.org\/10.1016\/j.intimp.2020.106972","journal-title":"Int Immunopharmacol"},{"key":"2859_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.103752","volume":"78","author":"S Dar","year":"2022","unstructured":"Dar S, Merza N, Qatani A et al (2022) Impact of proton-pump inhibitors on the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis. Ann Med Surg (Lond) 78:103752. https:\/\/doi.org\/10.1016\/j.amsu.2022.103752","journal-title":"Ann Med Surg (Lond)"},{"key":"2859_CR6","doi-asserted-by":"publisher","unstructured":"Li C, Xia Z, Li A, Meng J (2020) The effect of proton pump inhibitor uses on outcomes for cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ann Transl Med 8:1655\u20131655. https:\/\/doi.org\/10.21037\/atm-20-7498","DOI":"10.21037\/atm-20-7498"},{"key":"2859_CR7","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/ijc.33892","volume":"150","author":"YH Baek","year":"2022","unstructured":"Baek YH, Kang EJ, Hong S et al (2022) Survival outcomes of patients with nonsmall cell lung cancer concomitantly receiving proton pump inhibitors and immune checkpoint inhibitors. Int J Cancer 150:1291\u20131300. https:\/\/doi.org\/10.1002\/ijc.33892","journal-title":"Int J Cancer"},{"key":"2859_CR8","doi-asserted-by":"publisher","first-page":"16031","DOI":"10.1038\/s41598-018-34398-4","volume":"8","author":"HY Yoon","year":"2018","unstructured":"Yoon HY, Kim HN, Lee SH et al (2018) Association between neutrophil-to-lymphocyte ratio and gut microbiota in a large population: a retrospective cross-sectional study. Sci Rep 8:16031. https:\/\/doi.org\/10.1038\/s41598-018-34398-4","journal-title":"Sci Rep"},{"key":"2859_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju124","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, \u0160eruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/dju124","journal-title":"J Natl Cancer Inst"},{"key":"2859_CR10","first-page":"3098","volume":"8","author":"B Peng","year":"2015","unstructured":"Peng B, Wang YH, Liu YM et al (2015) Prognostic significance of the neutrophil to lymphocyte ratio in patients with non-small cell lung cancer: a systemic review and meta-analysis. Int J Clin Exp Med 8:3098\u20133106","journal-title":"Int J Clin Exp Med"},{"key":"2859_CR11","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2147\/OTT.S153290","volume":"11","author":"DB Sacdalan","year":"2018","unstructured":"Sacdalan DB, Lucero JA, Sacdalan DL (2018) Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco Targets Ther 11:955\u2013965. https:\/\/doi.org\/10.2147\/OTT.S153290","journal-title":"Onco Targets Ther"},{"key":"2859_CR12","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.cllc.2018.04.008","volume":"19","author":"A Zer","year":"2018","unstructured":"Zer A, Sung MR, Walia P et al (2018) Correlation of neutrophil to lymphocyte ratio and absolute neutrophil count with outcomes with PD-1 axis inhibitors in patients with advanced non\u2013small-cell lung cancer. Clin Lung Cancer 19:426\u2013434. https:\/\/doi.org\/10.1016\/j.cllc.2018.04.008","journal-title":"Clin Lung Cancer"},{"key":"2859_CR13","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.3390\/cancers11121954","volume":"11","author":"A Prelaj","year":"2019","unstructured":"Prelaj A, Ferrara R, Rebuzzi SE et al (2019) Epsilon: A prognostic score for immunotherapy in advanced non-small-cell lung cancer: a validation cohort. Cancers (Basel) 11:1954. https:\/\/doi.org\/10.3390\/cancers11121954","journal-title":"Cancers (Basel)"},{"key":"2859_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/cam4.1234","volume":"7","author":"T Shiroyama","year":"2018","unstructured":"Shiroyama T, Suzuki H, Tamiya M et al (2018) Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non\u2013small cell lung cancer. Cancer Med 7:13\u201320. https:\/\/doi.org\/10.1002\/cam4.1234","journal-title":"Cancer Med"},{"key":"2859_CR15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ejca.2020.12.012","volume":"145","author":"M Skribek","year":"2021","unstructured":"Skribek M, Rounis K, Afshar S et al (2021) Effect of corticosteroids on the outcome of patients with advanced non\u2013small cell lung cancer treated with immune-checkpoint inhibitors. Eur J Cancer 145:245\u2013254. https:\/\/doi.org\/10.1016\/j.ejca.2020.12.012","journal-title":"Eur J Cancer"},{"key":"2859_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00262-019-02453-2","volume":"69","author":"BE Wilson","year":"2020","unstructured":"Wilson BE, Routy B, Nagrial A et al (2020) The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies. Cancer Immunol Immunother 69:343\u2013354. https:\/\/doi.org\/10.1007\/s00262-019-02453-2","journal-title":"Cancer Immunol Immunother"},{"key":"2859_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.cllc.2022.12.013","volume":"24","author":"NT Sebastian","year":"2023","unstructured":"Sebastian NT, Stokes WA, Behera M et al (2023) The association of improved overall survival with NSAIDs in non-small cell lung cancer patients receiving immune checkpoint inhibitors. Clin Lung Cancer 24:287\u2013294. https:\/\/doi.org\/10.1016\/j.cllc.2022.12.013","journal-title":"Clin Lung Cancer"},{"key":"2859_CR18","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.annonc.2020.01.006","volume":"31","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Cardona A, Nagarkar DR et al (2020) Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol 31:525\u2013531. https:\/\/doi.org\/10.1016\/j.annonc.2020.01.006","journal-title":"Ann Oncol"},{"key":"2859_CR19","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s10637-020-00919-0","volume":"38","author":"T Ono","year":"2020","unstructured":"Ono T, Igawa S, Kurahayashi S et al (2020) Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors. Invest New Drugs 38:885\u2013893. https:\/\/doi.org\/10.1007\/s10637-020-00919-0","journal-title":"Invest New Drugs"},{"key":"2859_CR20","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.cllc.2018.04.021","volume":"20","author":"T Fukui","year":"2019","unstructured":"Fukui T, Okuma Y, Nakahara Y et al (2019) Activity of nivolumab and utility of neutrophil-to-lymphocyte ratio as a predictive biomarker for advanced non-small-cell lung cancer: a prospective observational study. Clin Lung Cancer 20:208\u2013214. https:\/\/doi.org\/10.1016\/j.cllc.2018.04.021","journal-title":"Clin Lung Cancer"},{"key":"2859_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.critrevonc.2019.07.005","volume":"142","author":"G Rossi","year":"2019","unstructured":"Rossi G, Pezzuto A, Sini C et al (2019) Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario. Crit Rev Oncol Hematol 142:26\u201334. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.07.005","journal-title":"Crit Rev Oncol Hematol"},{"key":"2859_CR22","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","volume":"30","author":"J Mazieres","year":"2019","unstructured":"Mazieres J, Drilon A, Lusque A et al (2019) Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: Results from the IMMUNOTARGET registry. Ann Oncol 30:1321\u20131328. https:\/\/doi.org\/10.1093\/annonc\/mdz167","journal-title":"Ann Oncol"},{"key":"2859_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/imm.12765","volume":"152","author":"GLV de Oliveira","year":"2017","unstructured":"de Oliveira GLV, Leite AZ, Higuchi BS et al (2017) Intestinal dysbiosis and probiotic applications in autoimmune diseases. Immunology 152:1\u201312. https:\/\/doi.org\/10.1111\/imm.12765","journal-title":"Immunology"},{"key":"2859_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108235","volume":"101","author":"W Fu","year":"2021","unstructured":"Fu W, Fu H, Ye W et al (2021) Peripheral blood neutrophil-to-lymphocyte ratio in inflammatory bowel disease and disease activity: a meta-analysis. Int Immunopharmacol 101:108235. https:\/\/doi.org\/10.1016\/j.intimp.2021.108235","journal-title":"Int Immunopharmacol"},{"key":"2859_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13037","volume":"49","author":"GL Erre","year":"2019","unstructured":"Erre GL, Paliogiannis P, Castagna F et al (2019) Meta-analysis of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in rheumatoid arthritis. Eur J Clin Invest 49:e13037. https:\/\/doi.org\/10.1111\/eci.13037","journal-title":"Eur J Clin Invest"},{"key":"2859_CR26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.intimp.2016.04.006","volume":"36","author":"Y Wu","year":"2016","unstructured":"Wu Y, Chen Y, Yang X et al (2016) Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were associated with disease activity in patients with systemic lupus erythematosus. Int Immunopharmacol 36:94\u201399. https:\/\/doi.org\/10.1016\/j.intimp.2016.04.006","journal-title":"Int Immunopharmacol"},{"key":"2859_CR27","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/jmv.25015","volume":"90","author":"J Gong","year":"2018","unstructured":"Gong J, Liang YL, Zhou W et al (2018) Prognostic value of neutrophil-to-lymphocyte ratio associated with prognosis in HBV-infected patients. J Med Virol 90:730\u2013735. https:\/\/doi.org\/10.1002\/jmv.25015","journal-title":"J Med Virol"},{"key":"2859_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7546047","volume":"2019","author":"H Xu","year":"2019","unstructured":"Xu H, Liu M, Cao J et al (2019) The dynamic interplay between the gut microbiota and autoimmune diseases. J Immunol Res 2019:7546047. https:\/\/doi.org\/10.1155\/2019\/7546047","journal-title":"J Immunol Res"},{"key":"2859_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/jvh.13216","volume":"27","author":"Y Zeng","year":"2020","unstructured":"Zeng Y, Chen S, Fu Y et al (2020) Gut microbiota dysbiosis in patients with hepatitis B virus\u2013induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. J Viral Hepat 27:143\u2013155. https:\/\/doi.org\/10.1111\/jvh.13216","journal-title":"J Viral Hepat"},{"key":"2859_CR30","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gutjnl-2015-310861","volume":"65","author":"MA Jackson","year":"2016","unstructured":"Jackson MA, Goodrich JK, Maxan ME et al (2016) Proton pump inhibitors alter the composition of the gut microbiota. Gut 65:749\u2013756. https:\/\/doi.org\/10.1136\/gutjnl-2015-310861","journal-title":"Gut"},{"key":"2859_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.642110","volume":"11","author":"C Huang","year":"2021","unstructured":"Huang C, Li M, Liu B et al (2021) Relating gut microbiome and its modulating factors to immunotherapy in solid tumors: a systematic review. Front Oncol 11:642110. https:\/\/doi.org\/10.3389\/fonc.2021.642110","journal-title":"Front Oncol"},{"key":"2859_CR32","doi-asserted-by":"publisher","first-page":"5458178","DOI":"10.1155\/2017\/5458178","volume":"2017","author":"GR Lee","year":"2017","unstructured":"Lee GR (2017) Phenotypic and functional properties of tumor-infiltrating regulatory T cells. Mediators Inflamm 2017:5458178. https:\/\/doi.org\/10.1155\/2017\/5458178","journal-title":"Mediators Inflamm"},{"key":"2859_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1146\/annurev-cancerbio-030518-055653","volume":"3","author":"JS Miller","year":"2019","unstructured":"Miller JS, Lanier LL (2019) Natural killer cells in cancer immunotherapy. Annu Rev Cancer Biol 3:77\u2013103. https:\/\/doi.org\/10.1146\/annurev-cancerbio-030518-055653","journal-title":"Annu Rev Cancer Biol"},{"key":"2859_CR34","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1111\/1759-7714.13677","volume":"11","author":"MG Choi","year":"2020","unstructured":"Choi MG, Kim YJ, Lee JC et al (2020) Efficacy of natural killer cell activity as a biomarker for predicting immunotherapy response in non-small cell lung cancer. Thorac Cancer 11:3337\u20133345. https:\/\/doi.org\/10.1111\/1759-7714.13677","journal-title":"Thorac Cancer"},{"key":"2859_CR35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jtho.2017.10.030","volume":"13","author":"J Tanizaki","year":"2018","unstructured":"Tanizaki J, Haratani K, Hayashi H et al (2018) Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab. J Thorac Oncol 13:97\u2013105. https:\/\/doi.org\/10.1016\/j.jtho.2017.10.030","journal-title":"J Thorac Oncol"},{"key":"2859_CR36","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3390\/diagnostics12020448","volume":"12","author":"YK Lee","year":"2022","unstructured":"Lee YK, Haam JH, Cho SH et al (2022) Cross-sectional and time-dependent analyses on inflammatory markers following natural killer cell activity. Diagnostics 12:448. https:\/\/doi.org\/10.3390\/diagnostics12020448","journal-title":"Diagnostics"},{"key":"2859_CR37","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, McCleod M, Hussein M et al (2019) Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20:924\u2013937. https:\/\/doi.org\/10.1016\/S1470-2045(19)30167-6","journal-title":"Lancet Oncol"},{"key":"2859_CR38","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","volume":"15","author":"R Jotte","year":"2020","unstructured":"Jotte R, Cappuzzo F, Vynnychenko I et al (2020) Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial. J Thorac Oncol 15:1351\u20131360. https:\/\/doi.org\/10.1016\/j.jtho.2020.03.028","journal-title":"J Thorac Oncol"},{"key":"2859_CR39","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/nejmoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378:2288\u20132301. https:\/\/doi.org\/10.1056\/nejmoa1716948","journal-title":"N Engl J Med"},{"key":"2859_CR40","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jtho.2020.09.022","volume":"16","author":"J Mazieres","year":"2021","unstructured":"Mazieres J, Rittmeyer A, Gadgeel S et al (2021) Atezolizumab versus docetaxel in pretreated patients with NSCLC: final results from the randomized phase 2 POPLAR and phase 3 OAK clinical trials. J Thorac Oncol 16:140\u2013150. https:\/\/doi.org\/10.1016\/j.jtho.2020.09.022","journal-title":"J Thorac Oncol"},{"issue":"6","key":"2859_CR41","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jtho.2022.02.003","volume":"17","author":"AM Hopkins","year":"2022","unstructured":"Hopkins AM, Badaoui S, Kichenadasse G et al (2022) Efficacy of atezolizumab in patients with advanced NSCLC receiving concomitant antibiotic or proton pump inhibitor treatment: pooled analysis of five randomized control trials. J Thorac Oncol 17(6):758\u2013767. https:\/\/doi.org\/10.1016\/j.jtho.2022.02.003","journal-title":"J Thorac Oncol"},{"key":"2859_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107347","author":"G Alkan \u015een","year":"2023","unstructured":"Alkan \u015een G, \u015eent\u00fcrk \u00d6zta\u015f N, De\u011ferli E et al (2023) Effect of antibiotic treatment on immune checkpoint inhibitors efficacy in patients with advanced non-small cell lung cancer. Lung Cancer. https:\/\/doi.org\/10.1016\/j.lungcan.2023.107347","journal-title":"Lung Cancer"},{"key":"2859_CR43","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cllc.2022.03.008","volume":"23","author":"T Yoneda","year":"2022","unstructured":"Yoneda T, Sone T, Koba H et al (2022) Long-term survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy in real-world settings. Clin Lung Cancer 23:467\u2013476. https:\/\/doi.org\/10.1016\/j.cllc.2022.03.008","journal-title":"Clin Lung Cancer"},{"key":"2859_CR44","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ejca.2021.08.036","volume":"157","author":"M Kostine","year":"2021","unstructured":"Kostine M, Mauric E, Tison A et al (2021) Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. Eur J Cancer 157:474\u2013484. https:\/\/doi.org\/10.1016\/j.ejca.2021.08.036","journal-title":"Eur J Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02859-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02859-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02859-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:03:58Z","timestamp":1761847438000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02859-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2859"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02859-2","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tomoki Hori, Kazuhiro Yamamoto, Takefumi Ito, Shigeki Ikushima, Tomohiro Omura, and Ikuko Yano declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective study involving human participants was conducted in compliance with the ethical standards of the institutional and national research committees and the 1964 Helsinki Declaration and its subsequent amendments or comparable ethical guidelines. The Ethics Committee of Nara Prefecture General Medical Center approved this study (Approval No. 706). Informed consent was obtained by allowing patients to opt-out of the study at any time by reviewing a summary of the study summary published on the institution\u2019s website.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Consent for publication was obtained from patients using an opt-out approach.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publish"}}]}}